Company Statement: Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
MLex Summary: Nasdaq-listed biotechnology company Amgen has agreed to acquire fellow Nasdaq-listed Oynx Pharmaceuticals for $10.4 billion.The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino...To view the full article, register now.
Already a subscriber? Click here to view full article